Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study of NRX-101 for Patients With Acute Complicated Urinary Tract Infection Including Pyelonephritis

Next Previous
X
Search
Trial Profile

An Open Label Study of NRX-101 for Patients With Acute Complicated Urinary Tract Infection Including Pyelonephritis

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cycloserine/lurasidone (Primary)
  • Indications Pyelonephritis; Urinary tract infections
  • Focus Therapeutic Use
  • Sponsors NeuroRX

    • Most Recent Events

    • 18 Dec 2023 According to a NRx Pharmaceuticals media release, the company announced that its Investigational New Drug Application (IND) for the use of NRX-101, the company's patented combination of D-cycloserine and lurasidone, for the treatment of complicated Urinary Tract infections (cUTI), received clearance from the US FDA.
    • 16 Nov 2023 New trial record
    • 13 Nov 2023 According to a NRx Pharmaceuticals media release, submitted an IND application with FDA to treat complicated Urinary Tract Infection (cUTI) with NRX-101 and Qualified Infectious Disease Product (QIDP) request response expected around year-end 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top